Q4 2017 ImmunoCellular Therapeutics Ltd Earnings Call
Llamada en conferencia ImmunoCellular Therapeutics Ltd
ImmunoCellular Therapeutics Ltd Conference call or earnings call will be held on 13-mar-2018 via an 800 number (toll-free). During the earnings conference call's session ImmunoCellular Therapeutics Ltd will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact ImmunoCellular Therapeutics Ltd for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Immunotherapy is an emerging approach to treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. While some other cancer immunotherapies only target a single cancer antigen, our technology can elicit an immune response against several antigens. Our cancer immunotherapies are also distinguished by the fact that they target cancer stem cells (CSCs), which are the primary drivers of tumor growth and disease recurrence. Our most advanced product candidate, ICT-107, recently began phase 3 testing in which we anticipate randomizing 414 patients in about 120 clinical sites in the U.S., Canada and Europe.Leer más Llamada en conferencia